Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
- Главная
- Библиотека
- Издания для врачей
- Гинекология
- Журнал «Гинекология» 2017
- Журнал «Гинекология» Том 19, №1 (2017)
- Клинический случай неэффективности консервативной терапии эндометриоза передней брюшной стенки с точки зрения возможной роли стволовых клеток
- ВКонтакте
- Viber
- РћРТвЂВВВВВВВнокласснРСвЂВВВВВВВРєРСвЂВВВВВВВ
- РњРѕР№ Р В Р’В Р РЋРЎв„ўР В Р’В Р РЋРІР‚ВВВВВВВРЎР‚
________________________________________________
Dubrovina S.O., Berlim Yu.D., Gimbut V.S. et al. The case of ineffective conservative treatment of endometriosis of anterior abdominal wall from the point of view of the possible role of stem cells. Gynecology. 2017; 19 (1): 63–65.
Клинический случай неэффективности консервативной терапии эндометриоза передней брюшной стенки с точки зрения возможной роли стволовых клеток
________________________________________________
Dubrovina S.O., Berlim Yu.D., Gimbut V.S. et al. The case of ineffective conservative treatment of endometriosis of anterior abdominal wall from the point of view of the possible role of stem cells. Gynecology. 2017; 19 (1): 63–65.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: экстрагенитальный эндометриоз, агонист гонадотропин-рилизинг-гормона, внутриматочная система с левоноргестрелом, стволовые клетки.
________________________________________________
Тhe article highlights the pathogenetic mechanisms of endometriosis outside the peritoneal cavity from the point of view of the role of bone marrow stem cells, given a possible explanation for the low efficiency of drug therapy of endometriosis outside the peritoneal cavity. The paper presents our own experience of using agonist of gonadotropin-releasing hormone intrauterine device with levonorgestrel at the same time.
Key words: extragenital endometriosis, agonist of gonadotropin-releasing hormone, levonorgestrel intrauterine system, stem cells.
2. Taylor HS, Osteen KG, Bruner-Tran KL et al. Novel therapies targeting endometriosis. Reprod Sci 2011; 18 (9): 814–23. DOI: 10.1177/1933719111410713.
3. Duke CM, Taylor HS. Stem cells and the reproductive system: historical perspective and future directions. Maturitas 2013; 76 (3): 284–9. DOI: 10.1016/j.maturitas.2013.08.012.
4. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003; 21 (2): 209–22.
5. Moggio A, Pittatore G, Cassoni P et al. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil Steril 2012; 98 (6): 1521–30.e2. DOI: 10.1016/j.fertnstert.2012.08.003.
6. Sakr S, Naqvi H, Komm B et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology 2014; 155 (4): 1489–97. DOI: 10.1210/en.2013-1977.
7. Kulak J Jr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; 152 (8): 3226–32. DOI: 10.1210/en.2010-1010.
8. Hufnagel D, Li F, Cosar E et al. The Role of Stem Cells in the Etiology and Pathophysiology of Endometriosis. Semin Reprod Med 2015; 33 (5): 333–40. DOI: 10.1055/s-0035-1564609.
________________________________________________
1. Klemmt PA, Carver JG, Koninckx P et al. Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: towards a mechanistic model for endometriosis progression. Hum Reprod 2007; 22 (12): 3139–47.
2. Taylor HS, Osteen KG, Bruner-Tran KL et al. Novel therapies targeting endometriosis. Reprod Sci 2011; 18 (9): 814–23. DOI: 10.1177/1933719111410713.
3. Duke CM, Taylor HS. Stem cells and the reproductive system: historical perspective and future directions. Maturitas 2013; 76 (3): 284–9. DOI: 10.1016/j.maturitas.2013.08.012.
4. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003; 21 (2): 209–22.
5. Moggio A, Pittatore G, Cassoni P et al. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil Steril 2012; 98 (6): 1521–30.e2. DOI: 10.1016/j.fertnstert.2012.08.003.
6. Sakr S, Naqvi H, Komm B et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology 2014; 155 (4): 1489–97. DOI: 10.1210/en.2013-1977.
7. Kulak J Jr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; 152 (8): 3226–32. DOI: 10.1210/en.2010-1010.
8. Hufnagel D, Li F, Cosar E et al. The Role of Stem Cells in the Etiology and Pathophysiology of Endometriosis. Semin Reprod Med 2015; 33 (5): 333–40. DOI: 10.1055/s-0035-1564609.
1. ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России. 344022, Россия, Ростов-на-Дону, Нахичеванский пер., д. 29;
2. ФГБУ «Ростовский научно-исследовательский институт акушерства и педиатрии» Минздрава России. 344012, Россия, Ростов-на-Дону, ул. Мечникова, д. 43
*s.dubrovina@gmail.com
________________________________________________
S.O.Dubrovina*1,2, Yu.D.Berlim1, V.S.Gimbut2, L.V.Krasilnikova1, K.A.Areshyan2, A.I.Lukash1
1. Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29;
2. Rostov Research Institute of Obstetrics and Pediatrics of the Ministry of Health of the Russian Federation. 344012, Russian Federation, Rostov-on-Don, ul. Mechnikova, d. 43
*s.dubrovina@gmail.com
- ВКонтакте
- Viber
- РћРТвЂВВВВВВВнокласснРСвЂВВВВВВВРєРСвЂВВВВВВВ
- РњРѕР№ Р В Р’В Р РЋРЎв„ўР В Р’В Р РЋРІР‚ВВВВВВВРЎР‚